Literature DB >> 22961993

Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.

Dimitrios Maltezas1, Meletios A Dimopoulos, Irene Katodritou, Panagiotis Repousis, Anastasia Pouli, Evangelos Terpos, Panayiotis Panayiotidis, Sossana Delimpasi, Evridiki Michalis, Konstantinos Anargyrou, Maria Gavriatopoulou, Aikaterini Stefanoudaki, Tatiana Tzenou, Efstathios Koulieris, Sotiris Sachanas, Maria Dimou, Theodoros P Vassilakopoulos, Maria K Angelopoulou, Gerassimos A Pangalis, Marie-Christine Kyrtsonis.   

Abstract

International Staging System (ISS), serum free light chain ratio (sFLCR) and lactate dehydrogenase (LDH) are well known, easily assessed independent prognostic indicators of outcome in multiple myeloma (MM). The purpose of the study was to re-examine the prognostic contribution of these variables in a multicenter setting with special attention to MM patients treated with autologous stem cell transplantation (ASCT) or novel agents (NA). Three hundred and five symptomatic newly diagnosed MM patients were retrospectively studied. Twenty-seven per cent, 32% and 41% were in ISS stages 1, 2, and 3, respectively. Fifty-six per cent of them presented kappa light chain monoclonality; median sFLCR was 27.04 (0.37-1.9 × 10(5) ) and 47.97 (0.26-2.3 × 10(7) ) for kappa patients and lambda patients, respectively; patients with sFLCR above median constituted the high sFLCR group. Thirty-one per cent of patients had increased LDH. As first line treatment, 55.7% received conventional treatment and 44.3% NA. After induction, 24% underwent ASCT, whereas 76% received NA at any line, either bortezomib (82.5%), thalidomide (48%) or lenalidomide (27%). When the 305 patients were analyzed together, staging, high sFLCR and abnormal LDH were predictive of survival. The same was true for patients that never received NA, whereas neither high sFLCR nor abnormal LDH constituted adverse factors in patients that received NA frontline. In the last group of patients, no difference was observed between ISS stages 2 and 3. The median 5-year survival of patients that never received NA versus those who did frontline was 29% vs 47%, 7% vs 52% and 24% vs 40% in patients with abnormal LDH, high sFLCR and ISS stage 3, respectively (p = 0.03, p < 0.00001 and p = 0.035). In conclusion, patients gaining the most from NA are those with an aggressive disease as reflected by advanced stage, abnormal LDH and high sFLCR. In addition, the adverse impact of these three variables is obscured by NA.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961993     DOI: 10.1002/hon.2026

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  7 in total

1.  Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.

Authors:  Junya Kuroda; Yuji Shimura; Kensuke Ohta; Hirokazu Tanaka; Hirohiko Shibayama; Satoru Kosugi; Shinichi Fuchida; Masayuki Kobayashi; Hitomi Kaneko; Nobuhiko Uoshima; Kazuyoshi Ishii; Shosaku Nomura; Masafumi Taniwaki; Akifumi Takaori-Kondo; Chihiro Shimazaki; Mitsuru Tsudo; Masayuki Hino; Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

2.  Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Authors:  Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Daisuke Kurita; Hitomi Sakagami; Hiromichi Takahashi; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

3.  Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.

Authors:  José Luis García de Veas Silva; Carmen Bermudo Guitarte; Paloma Menéndez Valladares; Johanna Carolina Rojas Noboa; Krysta Kestler; Rafael Duro Millán
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

4.  High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.

Authors:  Yan Gu; Ya-Hui Yuan; Ji Xu; Qing-Lin Shi; Xiao-Yan Qu; Rui Guo; Hua Bai; Jia-Dai Xu; Jian-Yong Li; Li-Juan Chen
Journal:  Oncotarget       Date:  2017-07-18

5.  Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.

Authors:  Michael Ghermezi; Mingjie Li; Suzie Vardanyan; Nika Manik Harutyunyan; Jillian Gottlieb; Ariana Berenson; Tanya M Spektor; Claudia Andreu-Vieyra; Sophia Petraki; Eric Sanchez; Kyle Udd; Cathy S Wang; Regina A Swift; Haiming Chen; James R Berenson
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

6.  Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Authors:  Lucia Lopez-Anglada; Cecilia Cueto-Felgueroso; Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Ana Lopez de la Guia; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Jose Mariano Hernandez; Miquel Granell; Francisco Javier Peñalver; Ramon Garcia-Sanz; Juan Besalduch; Yolanda Gonzalez; Rafael Benigno Martinez; Miguel Teodoro Hernandez; Norma C Gutierrez; Paloma Puerta; Antonio Valeri; Bruno Paiva; Joan Blade; Maria-Victoria Mateos; Jesus San Miguel; Juan Jose Lahuerta; Joaquin Martinez-Lopez
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

7.  Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.

Authors:  Ga-Young Song; Sung-Hoon Jung; Kihyun Kim; Seok Jin Kim; Sang Eun Yoon; Ho Sup Lee; Mihee Kim; Seo-Yeon Ahn; Jae-Sook Ahn; Deok-Hwan Yang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  BMC Cancer       Date:  2020-08-24       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.